A clinical study investigating the three months prognosis of patients with ischemic stroke treated with recombinant tissue plasminogen activator (rt-PA) and its effective factors

Objective: Currently, treating ischemic stroke by intravenous thrombolytic therapy has acceptable results in patients with stroke. This study aimed to evaluate the three months prognosis of patients treated with recombinant tissue plasminogen activator (rt-PA).Methods: This cross-sectional prospective study was conducted on ۳۰ patients with cerebral ischemic stroke with the National Institutes of Health Stroke Scale (NIHSS) >۵. Data such as demographic information, signs and symptoms, medical history, risk factors, focused neurological examination, and the NIHSS were collected for all patients. Then, all patients received ۰.۹ mg/kg of rt-PA as intravenous bolus doses and intravenous infusion under close monitoring in the emergency department. All patients were checked for necessary outcomes and also disability at the admission time, ۷ days later and after three months all patients were checked again. All collected data were analyzed by appropriate tests using SPSS version ۲۲.Results: Of all patients, ۶۳.۳% were males and ۳۶.۷% were females. The mean age of the patients was ۶۲.۳۷ ± ۱۲.۶۲ years with a range of ۴۰-۹۱ years. The mean of NIHSS was ۱۲.۴۶ ± ۴.۲۸ at admission time, in day seven it was ۸.۰۶ ± ۳.۷۲ and in month three after treatment it was ۳.۶۲ ± ۲.۳۱. There was a significant relationship between age, place of residence and NIHSS. Thirty percent of patients had NIHSS more than ۱۵ at admission time and after ۷ days this rate reached to ۱۰% and three months later it declined to ۶.۷%. These differences were statistically significant.Conclusion: Intravenous thrombolytic therapy is associated with proper short term results in most patients with ischemic stroke.

کلیدواژه ها:

Prognosis ، ischemic stroke ، Recombinant tissue plasminogen activator ، Ardabil